Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5551-5560 Newer>

The Motley Fool April 14, 2009 Brian Orelli	Sell Dendreon! No, Buy Dendreon! Dendreon, everyone's favorite tiny biotech, just got bigger because of positive phase 3 results for its prostate cancer treatment, Provenge.
The Motley Fool April 14, 2009	2 Stocks Hitting High Notes These stocks are bucking the trend.
InternetNews April 13, 2009 Alex Goldman	Veterans' Health Care Gets Data-Sharing Revamp The creation of a Joint Virtual Lifetime Electronic Record comes amid wider efforts to streamline health care through IT.
The Motley Fool April 13, 2009 Brian Orelli	Prescriptions for Acquisitions Express Scripts announces that it is buying WellPoint's NextRx pharmaceutical benefit management subsidiaries for almost $4.7 billion.
The Motley Fool April 13, 2009 Brian Orelli	Will These Drugs Get Past the FDA? Hopefully April won't bring showers of tears to these drugmakers: Eli Lilly... AstraZeneca... Bristol-Myers Squibb... Novo Nordisk... Johnson & Johnson...
The Motley Fool April 9, 2009 Brian Orelli	Cash: The Cure for Smaller Drugmakers For $60 million and a credit line of an additional $100 million, Merck licenses the rights to the oral formulation of vernakalant, Cardiome's atrial fibrillation treatment.
The Motley Fool April 9, 2009 Brian Orelli	The Side Effects of Competition In the pharmaceutical business, it's often the competitors that determine how bad the side effects can be.
Nursing Management April 2009 Sharon H. Pappas	Profits, Payers, and Patients: Responding to Changes Profit is necessary for hospitals to fulfill their missions, invest in expansion and new technologies, and reinvest in existing patient care infrastructures. Profitability is the work of the financial team and the clinical team to produce the hospital's desired financial outcome.
The Motley Fool April 7, 2009 Brian Orelli	Pfizer's Mind Meld Pfizer has a plan now for its structure after its acquisition of Wyeth -- including keeping eight senior executives from its new purchase.
The Motley Fool April 7, 2009 Brian Orelli	Bristol-Myers Squibb: On the Patent Cliff's Edge Bristol-Myers Squibb changed its huge patent cliff into two smaller falls with a larger ledge in the middle.
<Older 5551-5560 Newer> Return to current articles.